José Carballido

The discussion will focus on what has and hasn’t worked, why translation gaps persist for ASIT trials in T1D, MS, Rheumatoid Arthritis, Celiac Disease and other autoimmune diseases. Covering robust biomarker strategies for patient stratification, mechanistic endpoints, and proof-of-mechanism studies. Topics include measuring rare antigen-specific cells, emerging technologies, non-invasive monitoring – from immune phenotyping to leveraging preclinical models to de-risk studies. Perfect to bring your team to provide a shared framework to understand the success and failures in ASIT programs.

Join this workshop to:

• Understand the limitations of current antigen-specific biomarkers (e.g., tetramers, AIM assays) and how new technologies are addressing sensitivity and reproducibility issues
• Learn how leading labs are using biomarkers to stratify patients and define mechanistic endpoints in ongoing T1D and MS trials
• Identify strategies to bridge preclinical and clinical biomarker data, improving the predictivity of immune tolerance therapies